The DC50 of TD-802 was 12.5 nM, showcasing enhanced stability and tumor growth inhibition.71 AR-targeting PROTACs, such as ARCC-4 and ITRI-90, demonstrated superior efficacy in targeting mutated forms of AR and advanced into clinical trial for metastatic castration-resistant prostate cancer.357,359,360 ARV-766 and ARV-110361,362 are notable examples, achieving over 90% degradation of AR at nanomolar concentrations and are currently in Phase II clinical trials. The gene discussed is AR; the disease is neoplasm.